Introduction
The p53 tumour suppressor protein binds to speci®c DNA sequences and regulates the transcription of a number of genes involved in cell-cycle arrest and apoptosis. In normal cells, p53 is present at very low levels, but in response to various types of genotoxic stress including UV and ionizing radiation or chemical DNA damaging agents, p53 levels increase and can promote cell death or inhibition of proliferation (see reviews by Ko and Prives, 1996; Levine, 1997; Giaccia and Kastan, 1998) . Regulation of p53 occurs predominantly at the protein level and evidence suggests this is primarily mediated by the Mdm2 protein. Honda et al. (1997) have demonstrated that Mdm2 may act as a ubiquitin ligase which binds p53 and targets it to the proteasome and transfection of plasmids expressing Mdm2 into human cells accelerates p53 degradation (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997) . Molecules which bind to Mdm2 and block its interaction with p53, including antibodies (Blaydes et al., 1997) , or peptides based on p53 (Bottger et al., 1997) elevate the levels of p53 protein and its transcriptional activity. The potential for non-genotoxic cancer therapies based on these reagents is of considerable interest.
Attempts to knockout Mdm2 expression in transgenic mice resulted in non-viability, presumably due to unregulated p53 activity, while p53/Mdm2 double knockout mice were viable although susceptible to developing tumours in a manner similar to p53 knockouts (Jones et al., 1995; Montes de Oca Luna et al., 1995) . The deregulation of p53 in tumours further emphasises the importance of the relationship between p53 and Mdm2. The Mdm2 gene itself is a target of p53-dependent transcriptional activation and Mdm2 levels rise after induction of p53 following DNA damage of cells which express wild-type p53, providing a feedback loop which limits the p53 response by eventually returning protein levels to normal (Barak et al., 1993; Wu et al., 1993) . Many human tumours and tumour cell lines however express only transcriptionally inactive mutant p53 and consequently express little Mdm2. These tumours have constitutively high levels of their mutant p53 because the feedback loop cannot operate to control p53 protein levels (Midgley and Lane, 1997) . Other classes of tumours however retain active wild-type p53, but demonstrate alternative mechanisms of disabling the protein. Thirty per cent of human sarcomas show no p53 mutation but have an ampli®ed Mdm2 gene (Oliner et al., 1992) and 90% of cervical papillomas express HPV E6 which targets p53 for ubiquitination by recruitment of the E6-AP ubiquitin ligase (zur Hausen and Schneider, 1987) .
DNA damage by UV or ionizing radiation which activates the p53 response may act through Mdm2. Phosphorylation at the N-terminus of p53 after irradiation can decrease binding to Mdm2 (Shieh et al., 1997) , while UV irradiation reduces Mdm2 protein levels prior to induction of p53 (Wu and Levine, 1997; Blattner et al., 1999) . The human p14 p53-dependent indicating that the two proteins are involved in the same pathway. Consistent with this mouse embryo ®broblast cell lines which lack p19 ARF usually retain wild-type p53, while those that express p19 ARF show p53 mutation. Oncogenes including c-myc and E1A can induce p53, and promote apoptosis in mouse embryo ®broblasts through a mechanism which is independent of DNA damage, but is dependent on the presence of the p19 ARF protein de Stanchina et al., 1998) . It has now emerged that ARF physically interacts with Mdm2 and blocks Mdm2-dependent p53 degradation and transactivational silencing Pomerantz et al., 1998; Zhang et al., 1998) . The INK4a/ARF locus encodes both p16 INK4a , a cyclin-dependent kinase inhibitor which promotes Rb-dependent cell cycle arrest, and the alternative reading frame protein ARF (Quelle et al., 1995) . The INK4a/ARF locus is disrupted in human tumours almost as often as the p53 gene. Point mutations that inactivate p16
INK4a occur in a wide spectrum of tumours, and mutations such as deletions which aect both the p16
INK4a and p14 ARF genes are also common (Foulkes et al., 1997; Ruas and Peters, 1998) . However many of the mutations that aect both p14 ARF and p16
INK4a may not aect p14 ARF function . Initially it was thought that point mutations that exclusively disrupt p14 ARF were rare since they were not found in the exon 1b encoded N-terminal domain of p14 ARF which is sucient to induce cell cycle arrest. However, the discovery of point mutations in exon 2 of p14 ARF which may be required for nucleolar localization, and blocking of p53 nuclear export (Zhang and Xiong, 1999) showed that both proteins are frequently disrupted in human cancers. In addition mice lacking only the exon 1b sequences of p19 ARF are highly cancer prone and embryo ®broblasts from these animals cannot undergo replicative scenescence and can be transformed by activated ras alone (Kamijo et al., 1997) .
Degradation of p53 by the 26S proteasome requires polyubiquitination of p53 (Maki et al., 1996) which involves a three step enzymic process (reviewed in Hershko and Ciechanover, 1998) : First the E1 enzyme carries out activation of ubiquitin by forming a thioester bond between a conserved cysteine in the enzyme's active site and glycine 76 at the C-terminal end of ubiquitin. The ubiquitin is then passed on to the ubiquitin conjugating enzyme or E2, again forming a thioester bond between ubiquitin and the E2 and ®nally E2 transfers the activated ubiquitin to a lysine residue of the substrate either directly, or with the help of a third ubiquitin ligating enzyme (E3). Most species have one E1 but multiple E2 and E3 enzymes. It is largely the E3 which confers substrate speci®city, and in the case of p53, the ubiquitin ligase appears to be Mdm2 in normal cells (Honda et al., 1997) and E6/E6-AP in papilloma virus infected cells (Schener et al., 1993) . p53 ubiquitination has been achieved in vitro using cell extracts expressing ubiquitinating proteins E1, UbcH5 (E2) and Mdm2 (Honda et al., 1997; Honda and Yasuda, 1999) . In this study we have used puri®ed components to con®rm that human Mdm2 can mediate ubiquitination of p53 and we have also shown that Mdm2 is itself ubiquitinated in vitro. We have identi®ed a synthetic p14 ARF N-terminal peptide which is sucient to bind Mdm2, and show that this peptide can speci®cally block in vitro ubiquitination of p53 and ubiquitination of Mdm2. Deletion mapping of the binding site of the peptide shows binding to the central acidic domain of Mdm2 at a site distant to the p53 binding domain (Momand et al., 1992; Oliner et al., 1993) , but adjacent to the binding site of an Mdm2 speci®c antibody, 2A10 which on microinjection into tumour cells can induce transcriptional activation of a p53-dependent reporter plasmid. When fused to Green uorescent protein (GFP) the N-terminal p14 ARF peptide elevated p53 levels and induced transcriptional activation of p53 in vivo. This suggests that proteins in the cell that bind to this region of Mdm2 may block its ubiquitinating ability, and that molecules based on p14 ARF peptides or antibody 2A10 could provide novel non-genotoxic activators of p53 for use in cancer therapy.
Results
An N terminal peptide of p14 ARF is sufficient for Mdm2 binding An overlapping series of biotinylated synthetic peptides (20-mers overlapping by 10 amino acids, Figure 1a and b) representing the whole of human p14 ARF (Peptides 3 ± 15) and the N-terminal part of mouse p19 ARF encoded by exon 1b (Peptides 19 ± 24) was tested for the ability to bind to human Mdm2 puri®ed from bacteria. ELISA plates were coated with streptavidin followed by the biotinylated peptides in series. Mdm2 protein was added to the ELISA plate, and after extensive washing, bound Mdm2 was detected with antibody 4B2. Only Peptide 3 (amino acids 1 ± 20: MVRRFLVTLRIRRACGPPRV) in the 20-mer p14 ARF series bound Mdm2 (Figure 1c) Figure  1e ), suggesting that the ®rst 15 residues are sucient. p14 ARF 20-mer Peptide 3 however consistently showed greater binding than 15-mer Peptide 16 so further analysis of Peptide 3 was carried out. The Pepscan ELISA was also performed with human p53 puri®ed from a bacterial expression system by the same method described for Mdm2. Peptide 3 did not bind to human p53 in this assay (results not shown) indicating that the interaction with Mdm2 is speci®c.
Anti-Mdm2 antibody 2A10 blocks binding of Peptide 3 to Mdm2 and can activate p53 protein in vivo It has been shown previously that the interaction between p53 and the Mdm2 protein can be blocked using the N-terminal anti-Mdm2 antibody 3G5 (Blaydes et al., 1997) . Microinjection of 3G5 into T22 cells stably transfected with the p53-responsive transcriptional reporter plasmid pRGCDFosLacZ (Hupp et al., 1995) induces an increase in p53 protein levels and in p53-dependent transcriptional activation demonstrated by b-galactosidase staining (Figure 2a and Blaydes et al., 1997; Midgley and Lane, 1997) . While screening antibodies that bind to other regions of Mdm2 we found another antibody 2A10, which also induced p53-dependent transcriptional activation (Figure 2a) . This antibody does not block the interaction between p53 and Mdm2 (the proteins are coprecipitated by 2A10, results not shown), suggesting that another mechanism is involved. We looked at the relationship between Peptide 3 and 2A10 by conducting the peptide binding ELISA with Mdm2 that had been preincubated with 2A10, or a control antibody 4B11 and found that only 2A10 blocked the binding of Mdm2 to Peptide 3 (Figure 2b ). This suggests that Peptide 3 and antibody 2A10 might bind at the same or adjacent sites within the Mdm2 protein.
Mapping of p14
ARF Peptide 3 and 2A10 binding sites on Mdm2
A series of deletions from the C-terminus of the Mdm2 protein were expressed by in vitro translation ( Figure  3a) . To map the binding site of Peptide 3, biotinylated Peptide 3, or control p14 ARF Peptide 9 (amino acids 61 ± 80) which did not bind Mdm2, were bound to streptavidin beads that were then used to pull down bound proteins from the in vitro translation extracts. Peptide 3 was able to pull down a truncated protein containing amino acids 1 ± 244, but not amino acids 1 ± 212, while a protein including amino acids 1 ± 232 was coprecipitated weakly (Figure 3b A similar immunoprecipitation assay using antibody 2A10 was able to pull down a truncated Mdm2 protein containing amino acids 1 ± 258 but not one containing amino acids 1 ± 244 (Figure 3b ) suggesting that 2A10 binds in the region 244 ± 258, adjacent to the Peptide 3 binding site. Antibody 4B2 which binds close to the Nterminus of Mdm2 (Chen et al., 1993) immunoprecipitated all of the truncated proteins. 2A10 was also able to immunoprecipitate Mdm2 and truncated Mdm2 proteins from Saos2 cells transfected with Mdm2 expression plasmids (results not shown). However a fusion protein containing the C-terminal 186 amino acids of Mdm2 was still able to bind 2A10 weakly suggesting a second binding site exists in the Cterminus, (results not shown, C Blattner in preparation).
A GFPPeptide 3 fusion protein can induce endogenous p53 protein levels in vivo
To facilitate the study of Peptide 3 activity in vivo, a fusion of Peptide 3 was made to the C-terminus of Green Fluorescent Protein (GFP) by inserting in-frame synthetic oligonucleotides encoding the peptide into the mammalian expression vector pEGFPC2 (Clontech). Plasmids expressing GFP or GFP-Peptide 3 were transfected into MCF7 cells (which express active p53) using Fugene 6 2 transfection reagent. GFP was strongly expressed throughout the transfected cells while GFP-Peptide 3 was expressed largely in the nucleus (Figure 4a ). Where high levels of nuclear GFPPeptide 3 expression were observed, co-staining with the rabbit anti-p53 serum CM1 detected with a Texas red labelled secondary antibody showed elevated endogenous p53 staining. Transiently transfected MCF7 cells were lysed and subjected to Western blotting with anti-p53 antibody DO-1, with mouse anti-GFP and with anti-PCNA antibody PC10. PCNA levels were similar indicating equal protein loading. Overall expression of GFP-Peptide 3 in transiently transfected cells was always very low ( Figure 4b ) compared to expression of control GFP and GFPAntisense Peptide (where the oligonucleotides encoding Peptide 3 were inserted into pEGFPC2 in-frame, but in the wrong orientation). In transfections carried out in parallel only 10 ± 15% of the cells expressed detectable levels of GFP-Peptide 3 (assessed by¯uorescence microscopy, data not shown). Nevertheless expression of GFP-Peptide 3 consistently resulted in induction of endogenous p53 protein levels while transfection of plasmids expressing GFP or the GFP-Antisense Peptide fusion did not elevate p53 levels. The increase in p53 protein levels elicited by GFP-Peptide 3 was however smaller than that resulting from expression of full-length p14 ARF . A U-2 OS cell line (which also expresses functional endogenous p53) stably transfected with tetracycline- The assay was performed in duplicate inducible plasmid pCAMTet GFP-Peptide 3 was incubated with the water soluble tetracycline derivative doxycycline (1 mg/ml) for 24 h to induce GFP-Peptide 3 expression. Again a consistent elevation in endogenous p53 levels was detected (Figure 4c ). PCNA levels on membranes were constant indicating equal protein loading.
A GFP-Peptide 3 fusion protein can activate a p53-responsive reporter plasmid in vivo Lysates of U-2 OS cells co-transfected with plasmids expressing p14 ARF , GFP, GFP-Antisense Peptide or GFP-Peptide 3, together with the p53-responsive pRGCDFosLacZ reporter, were analysed by a quantitative b-galactosidase assay employing the chromogenic substrate CPRG (Figure 5 ). At concentrations between 6.25 and 50 ng of transfected plasmid DNAs p14 ARF strongly induced b-galactosidase expression. A modest induction was also achieved with GFP-Peptide 3 that was consistently higher than transfections with control plasmids. This indicates that expression of GFPPeptide 3 enhanced the level of p53 transactivation activity.
Peptide 3 blocks Mdm2-dependent p53 ubiquitination in vitro p14
ARF activates p53-dependent transcription and has been reported to block Mdm2-mediated ubiquitination of p53 (Honda and Yasuda, 1999) . As p14 ARF derived Peptide 3 expressed as a GFP fusion protein also activates p53 and increases p53 levels, we assessed the ability of Peptide 3 to interfere with Mdm2-mediated ubiquitination of p53. Polyubiquitination of p53 can be recapitulated in vitro in a reaction which uses in vitro translated 35 S-labelled p53 as substrate and requires the presence of puri®ed recombinant human E1, UbcH5 and Mdm2, ubiquitin and ATP. Polyubiquitination of p53 required the presence of each of these components (Figure 6a ). Addition of Peptide 3 to the assay dramatically decreased modi®cation to levels observed in the absence of Mdm2, when only mono-and diubiquitin adducts of p53 are observed. Neither p14 ARF derived Peptide 9, which does not bind Mdm2, nor a peptide with the same amino acid composition as Peptide 3, but randomly arranged sequence, inhibited Mdm2 mediated polyubiquitination of p53 (Figure 6b) . A peptide containing a substitution of alanine for cysteine at position 15 has wild-type inhibitory activity (Figure 6b ), indicating that inhibition is not a consequence of a non-speci®c di-sulphide bond formation between cysteine 15 and the cysteine residue within the putative active site of Mdm2 (Honda et al., 1997) . Quantitation of ubiquitinated forms of p53 was obtained after phosphorimaging and Figure 6c shows the relative inhibitory eect of the peptides.
Inhibition of Mdm2-mediated polyubiquitination of p53 could be accomplished by a number of dierent mechanisms. The p14 ARF derived Peptide 3 may inhibit the intrinsic enzymatic activity of Mdm2, or alternatively may alter the ability of Mdm2 to utilize its p53 substrate. To distinguish between these possibilities we determined the ability of p14 ARF derived peptides to inhibit the ubiquitination of Mdm2 itself. In the presence of 125 I-labelled ubiquitin, recombinant puri®ed E1, UbcH5, and ATP, Mdm2 itself undergoes ecient ubiquitination (Figure 7a , ®rst lane). Omission of any of the puri®ed proteins reduces ecient ubiquitination of Mdm2. Addition of puri®ed p53 to the in vitro (Figure 7a , last lane) although it is not possible to distinguish between the polyubiquitinated products of p53 and Mdm2 in this experiment. Again Peptide 3 but not Peptide 9 was able to signi®cantly inhibit the combined ubiquitination of p53 and Mdm2 (Figure 7b ) and also the ubiquitination of Mdm2 itself in the absence of p53 (Figure 7c ).
Peptide 3 does not interfere with the ability of E1 or UbcH5 to form a thioester with ubiquitin While Peptide 3 binds Mdm2 and interferes with Mdm2-mediated ubiquitination it was important to rule out the possibility that Peptide 3 was also interfering with another step in the ubiquitination cascade. The enzymatic activity of E1 and UbcH5 was therefore tested in a thioester assay in the presence or absence of Peptide 3 and Peptide 9. In the thioester assay the ability of recombinant ubiquitination enzymes to form a thioester adduct with 125 I-ubiquitin in the presence of ATP can be analysed by SDS ± PAGE under non-reducing conditions. In the presence of E1 and 125 I-ubiquitin, an E1-ubiquitin thioester product is detected and this is unaected by the presence of Peptide 3 or Peptide 9 (Figure 8 ). When UbcH5 is added to the E1 and 125 I-ubiquitin reaction, an additional labelled species is detected. Again neither Peptide 3 nor Peptide 9 alter the extent of thioester formation.
Discussion
The search for molecules that might be used therapeutically to activate wild-type p53 or reactivate mutant p53s in tumour cells in order to restore the apoptotic response has revealed a number of possible mechanisms. A negative regulatory domain at the Cterminus of p53 can be neutralized by binding of certain antibodies and peptides (Hupp and Lane 1994; Hupp et al., 1995; Shaw et al., 1996) , allowing the DNA binding domain to become fully functional. This may mimic events which occur on p53 activation in normal cells, such as phosphorylation, acetylation or binding of cellular proteins (reviewed in Giaccia and Kastan, 1998; Ko and Prives, 1996) . Similarly there is some evidence that the N-terminus of p53 may also harbour negative regulatory domains which communicate with the DNA binding domain and which aect thermostability and transactivation (Hansen et al., 1998; Liu and Lane, personal communication) . In the absence of a functional p53-activating stimulus Mdm2 targets p53 for degradation via the ubiquitin-proteasome pathway and keeps the level of p53 low. In addition, the association of Mdm2 with p53 inhibits the transactivation activity of p53. Molecules which (Bottger et al., 1997) . ARF is the most recently discovered activator of p53. Through binding to Mdm2 it is able to prevent Mdm2 mediated degradation of p53 and to overcome the inhibitory eect of Mdm2 on p53 transactivation activity. ARF does this without directly competing with p53 for Mdm2 binding (Zhang et al., 1998) . In this study we wanted to achieve the initial stages of identifying and characterizing small peptides which might mimic the activity of the ARF protein.
Expression of p14 ARF exon 1b alone (amino acids 1 ± 64) is sucient to stabilize p53 and induce cell cycle arrest (Zhang et al., 1998; Kamijo et al., 1998; Stott et al., 1998 ) but a de®nitive binding motif has not been described. In vitro assays with a series of overlapping synthetic peptides demonstrated that a binding site for Mdm2 occurs within the N-terminal 15 amino acids of the human p14 ARF and mouse p19 ARF proteins. As peptides containing the ®rst 20 amino acids of p14 ARF (Peptides 3) or p19 ARF (Peptide 19) consistently bound more eciently in the ELISA assay than those peptides with only the ®rst 15 amino acids, the 20 amino acid Peptide 3 sequence was used throughout the rest of the analysis. p19 ARF Peptides 20 (amino acids 11 ± 30) and 21 (amino acids 21 ± 40) showed a low level of Mdm2 binding activity suggesting that p19 ARF may contain a binding site in addition to the one in its ®rst 15 amino acids. An R*FLV motif is present in both p19 ARF and p14 ARF at amino acids 4 ± 7 and is repeated at amino acids 21 ± 24 of p19 ARF . Further studies are required to determine whether this motif is important for binding to Mdm2.
We examined the eect of p14 ARF Peptide 3 on p53 expression and activity in vivo. Endogenous p53 levels were increased in an inducible U-2 OS cell line expressing p14 ARF Peptide 3 fused at its N-terminus to GFP. Transient expression of GFP-Peptide 3 also elevated endogenous p53 levels in MCF7 cells, while control GFP or GFP-Antisense Peptide 3 had no eect. Protein levels of the GFP-Peptide 3 fusion were very low compared to GFP or GFP-Antisense Peptide which may re¯ect inecient expression, or instability of the fusion protein. Co-staining of transfected cells with the anti-p53 antibody CM1 showed that high levels of GFP-Peptide 3 in the nucleus of cells correlated with elevated p53 protein. The nuclear location of GFPPeptide 3 also suggests that it may associate with another nuclear protein in vivo as GFP is normally expressed throughout the cell. It is also conceivable that the basic nature of the arginine-rich Peptide 3 sequence could allow it to function as a nuclear S-labelled p53 was incubated in an ATP regenerating system with ubiquitin (Ub), Ub activating enzyme (E1), UbcH5 and Mdm2 as indicated. Reaction products were fractionated by SDS ± PAGE, and the dried gel was analysed by phosphorimaging. (b) Peptide 3 (PEP3), control Peptide 9 (PEP9), a random control peptide (composed of the same constituent residues as Peptide 3) and a peptide with a substitution of alanine for cysteine 15 were assayed for their eect on the in vitro ubiquitination of p53. Peptides were added at 6 mM and DMSO (resuspension solvent) alone was added as negative control in the reaction shown in the last lane. Samples were treated as described above. The positions of p53 and polyubiquitinated form of p53 are indicated. (c) Quantitation of the inhibitory eect of the peptides localization sequence. Our second in vivo assay analysed activation of a p53 responsive reporter construct (RGCDFosLacZ). At a range of concentrations, GFP-Peptide 3 gave a consistent activation of bgalactosidase expression compared with GFP and GFP-Antisense Peptide control plasmids. GFP-Peptide 3 is thus able to increase endogenous p53 protein expression and increase the level of p53 transactivation activity in cells.
Mdm2 has been reported to act as an E3 ubiquitin ligase which can mediate the polyubiquitination of p53. Honda et al. (1997) have developed an in vitro Mdm2 ubiquitination assay using total lysate extracts of Sf9 insect cells expressing GST-Mdm2. In this assay Mdm2 can mediate polyubiquitination of GST-p53 in the presence of mouse E1 and human UbcH5 (E2). Polyubiquitination targets proteins for degradation by the 26S proteasome. Ubiquitinated forms of p53 are decreased after UV irradiation (Maki and Howley, 1997) , suggesting that modulation of the ubiquitinproteasome system is at least partly responsible for the stabilization of p53 after some types of DNA damage. There is evidence that ARF is able to inhibit the ubiquitin ligase activity of Mdm2 towards p53. It was demonstrated that a co-immunoprecipitate of HisMdm2 bound to GST-p19 ARF had decreased ubiquitinating activity compared to unbound His-Mdm2 (Honda and Yasuda, 1999) . In order to pursue the mechanism of p14 ARF Peptide 3 activity we have developed an in vitro ubiquitination assay using puri®ed protein components: human E1 puri®ed from a baculovirus system and human UbcH5 and Mdm2 puri®ed from E. coli. Using 35 S-methionine labelled p53 made by in vitro translation in wheat germ extracts we have shown that Mdm2 mediates the polyubiquitination of p53 in the presence of E1 and UbcH5. In a second form of the assay the substrate was p53 puri®ed from infected baculovirus cells and the reaction was performed with iodinated ubiquitin. The reactions that lack p53 or use p53 puri®ed from baculovirus infected cells contain only puri®ed components and therefore no source of contaminating ubiquitinating proteins. We show that Mdm2 eciently mediates the ubiquitination of p53 in vitro, and also that Mdm2 itself is ubiquitinated (Figure 7a , compare the ®rst and last lanes). The mechanism of ubiquitination of Mdm2 remains unclear. We cannot distinguish between true Mdm2 intra-molecular autoubiquitination, ubiquitination by a second Mdm2 molecule, or indeed direct ubiquitination by UbcH5 in this assay. Addition of p14 ARF Peptide 3 but not control Peptide 9 or a`Random' peptide inhibits both p53 ubiquitination and ubiquitination of Mdm2 itself (Figure 7b and c) . In order to determine at which stage p14 ARF Peptide 3 inhibits the ubiquitination reaction, we performed a thioester assay using iodinated ubiquitin ( 125 I-Ub). The formation of a thioester bond with ubiquitin is a characteristic of E1 and E2 as well as E3 activity. Peptide 3 did not block formation of 125 I-Ub-E1 and 125 I-Ub-UbcH5 thioesters (no ubiquitinated UbcH5 was detected in the absence of E1 as expected) indicating that the transfer of ubiquitin to the E1 or E2 (UbcH5) is not the target of Peptide 3 inhibition. This con®rms that the peptides speci®cally inhibit the ®nal stage i.e. transfer of ubiquitin to p53 or Mdm2 itself, and that the peptides are not simply non-speci®c inhibitors of the ubiquitination assays. Inhibition of the ubiquitin ligase activity of Mdm2 towards p53 by GFP-Peptide 3 is a mechanism by which GFP-Peptide 3 could increase p53 expression in intact cells. We were also unable to detect a signi®cant eect of GFP-Peptide 3 in colony survival assays to determine whether it could act as a tumour suppressor. We are currently trying to improve the ecacy of Peptide 3 fusion proteins in the in vivo assays by improving its expression. Expression of GFP fusion proteins may be limited by the cytotoxic eects of high levels of GFP (Liu et al., 1999) . Alternative peptide-fusion proteins will be used in future work. While peptides derived from the ®rst 15 ± 20 amino acids of ARF displayed the strongest Mdm2 binding activity a peptide consisting of amino acids 21 ± 40 from p19 ARF also bound weakly to Mdm2. The anity of peptides for Mdm2 may consequently be improved by using a longer region from the N-terminus of p19 ARF which appears to contain an Mdm2 binding site in addition to the one in the ®rst 15 amino acids. The use of in vitro phage selection techniques has also been previously successful in generating peptides with higher binding anities for Mdm2 (Bottger et al., 1996) . In addition to its ability to inhibit the ubiquitin ligase activity of Mdm2 another suggested mechanism for p14 ARF activity is nucleolar sequestration of Mdm2, which may prevent association with p53 in the nucleoplasm (Weber et al., 1999; Tao and Levine, 1999 ). Mdm2 appears to export p53 from the nucleus to the cytoplasm where it can then be degraded by the 26S proteasome (Roth et al., 1998; Freedman and Levine, 1998; Lain et al., 1999) . Cell staining experiments have shown that ARF proteins are largely restricted to the nucleolus and that overexpression of ARF draws Mdm2 but not p53 into the same subnuclear compartment. An ARF mutant that binds Mdm2 but does not move it to the nucleolus cannot induce a p53-dependent cell cycle arrest. It is possible that both mechanisms, i.e. nuclear sequestration and inhibition of Mdm2 ubiquitin ligase activity, contribute to the eects of ARF. GFP-Peptide 3 fusion protein expression was not restricted to the nucleolus and is thus unlikely to act by nucleolar sequestration of Mdm2. The weak p53 activating activity of GFPPeptide 3 compared to the p14 ARF protein in vivo may re¯ect this. The addition of a nucleolar targeting sequence to Mdm2 binding ARF peptides may improve their ecacy in activating p53.
Since binding of Peptide 3 to Mdm2 was able to regulate Mdm2 function it was of interest to map the Peptide 3 binding site on Mdm2. This might provide a good target site for Mdm2 directed therapeutic intervention. A p19 ARF -Flag fusion protein has been shown to interact with a truncated Mdm2 protein including amino acids 1 ± 222 but not with a shorter protein including amino acids 1 ± 154 (Pomerantz et al., 1998) . Residues 154 ± 221 in Mdm2 therefore appeared important for p19 ARF interaction, although an internal 154 ± 222 deletion retained some association with p19 ARF suggesting that other regions may contribute to binding. In mapping experiments using in vitro translated truncated Mdm2 proteins, we have identi®ed a binding site for p14 ARF Peptide 3. This was located between amino acids 212 and 244 of Mdm2. In a survey of antibodies which could induce p53-dependent activation of a reporter cell line we identi®ed an antiMdm2 antibody 2A10 which was reported to bind close to this region of Mdm2 (Chen et al., 1993) . 2A10 was able to block the binding of Mdm2 to Peptide 3 in the ELISA assay. Molecules which bind this region of Mdm2 may thus aect the ability of Mdm2 to negatively regulate p53 activity. A number of other cellular proteins have been reported to bind in or near to this domain of Mdm2. The retinoblastoma protein (Rb) binds Mdm2 close to this region (amino acids 273 ± 321) and can overcome the anti-apoptotic function of Mdm2, and the Mdm2-dependent degradation of p53 (Hsieh et al., 1999) . However while p53 protein is elevated in cells transfected with Rb, the resulting trimeric p53/Mdm2/Rb complex is not transcriptionally active suggesting that something more than a simple block to p53 degradation may be required for full restoration of the transactivation functions of p53. The transcriptional coactivator p300 binds both Mdm2 (amino acids 102 ± 222) and the N-terminus of p53, and can have both negative and positive eects on p53 activity (Grossman et al., 1998) . p300 may be able to enhance the transactivation activity of p53 by altering chromatin structure through histone acetylation at certain promoters (Korsus et al., 1998) and by directly acetylating the C-terminus of p53 (Gu and Roeder, 1997) . However it has been suggested that the interaction of p300 complexes with Mdm2 may facilitate Mdm2 mediated ubiquitination of p53 and its subsequent degradation (Grossman et al., 1998) . ARF proteins might compete with p300 for Mdm2 binding in vivo, reduce degradation-dependent downregulation of p53 and allow p300 to act as a transcriptional coactivator of p53 rather than an inhibitor.
In summary our results demonstrate that the 20 amino acid Peptide 3 derived from the N-terminus of p14 ARF can inhibit Mdm2-dependent p53 ubiquitination in vitro, supporting previous evidence that ARF proteins act as inhibitors of Mdm2-dependent ubiquitination. In addition we have achieved induction of p53 protein in vivo, both in terms of elevated expression and transactivation of a transcriptional reporter by expression of a GFP-Peptide 3 fusion protein in the nucleus. We hope that improving the binding anity and expression level of the peptide-fusion protein will provide an ecient inhibitor of Mdm2-mediated p53 inhibition, and contribute to the development of nongenotoxic activators of p53.
Materials and methods

Antibodies and plasmids
Monoclonal antibodies 4B2, 3G5, 4B11 and 2A10 (Chen et al., 1993) recognise human and mouse Mdm2. CM1 rabbit antiserum and mouse monoclonal antibody DO-1 recognize human p53. Mouse anti-GFP antibody was supplied by Boehringer Mannheim. Monoclonal antibody PC 10 recognizes human PCNA. To create the Mdm2 deletion series an EcoRI fragment encoding Mdm2 was transferred from plasmid pCOC-Mdm2 X2 (Barak et al., 1994) to pcDNA3. pcDNA3 Mdm2 was linearized with ApaI and NotI then exonuclease III was used to delete from the 3' end following the procedure described in Sambrook et al. (1989) . Plasmids expressing a GFP-Peptide 3 fusion protein were created by inserting phosphorylated and annealed synthetic oligonucleotides (5'-GTGCGCAGGTTCTTGGTGACCCTCCGGATT-CGGCGCGCGTGCGGCCCGCCGCGAGTG and 5'-CAC-TCGCGGCGGGCCGCACGCGCGCCGAATCCGGAGG-GTCACCAAGAACCTGCGCAC) into the SmaI site of pEGFPC2 (Clontech). The complete GFP-Peptide 3 fragment was also inserted into the tetracycline-inducible mammalian expression vector pCAMTet (constructed by inserting fragments carrying the CMV promoter and rtTA gene (tetR r -VP16 fusion) from pUHD172-1neo (Gossen et al., 1995) and the PhCMV*-1 regulatory promoter from pUHG 10-3 (Gossen and Bujard, 1992) into pcDNA3) to create pCAMTet GFP-Peptide3. pRGCDfoslacZ was a gift from SH Friend.
Cell culture and transfection
MCF7 breast tumour cells (Vojtesek and Lane, 1993) and U-2 OS osteosarcoma cells (Florenes et al., 1994) both express functionally wild-type p53 and were cultured at 378C in Dulbecco's modi®ed Eagle's medium (DMEM, Gibco) supplemented with 10% foetal calf serum and gentamycin (50 mg/ml). Transfections were performed with Fugene 2 6 transfection reagent (Boehringer Mannheim) following manufacturers instructions. pBS plasmid DNA was added where necessary to make DNA concentrations identical in each transfection. Transient transfections were harvested after 48 h. Stable cell lines expressing tetracycline-inducible plasmids were selected for 4 weeks in medium containing 1 mg/ml Geneticin G418 (Gibco ± BRL) and individual colonies were grown up separately. Selection of the mouse ®broblast reporter cell line T22 RGCDfosLacZ was described in Hupp et al. (1995) .
Expression and purification of recombinant proteins
Human p53 protein was expressed in baculovirus infected Sf9 cells and puri®ed on a heparin sepharose column as described in Hansen et al. (1996) .
A cDNA encoding human Mdm2 (amino acids 6 ± 491) was inserted into plasmid pT7-7 and expressed in BL ± 21(DE3) bacteria after IPTG induction as described in Midgley et al. (1992) . Under these conditions most of the protein was insoluble, so partial puri®cation could be carried out by isolating the bacterial inclusion bodies. In brief, the cell pellet from a 1 litre culture was washed in ice cold 50 mM Tris HCl pH 8.0, weighed and resuspended at 0.66 mg/ml in lysis buer (10% sucrose, 50 mM Tris HCl pH 8.0). 15 ml of 10 mg/ml lysozyme and 20 ml 5 M NaCl were added per ml of cell suspension which was then chilled in a melting ice bath for 1 h. The tube was warmed at 378C for 1 min then returned to the ice bath. Chilling and warming was repeated until complete lysis occurred, then viscosity was reduced by gentle sonication. Insoluble proteins were pelleted by centrifugation at 10 000 g and the pellet washed three times by resuspending in wash buer (50 mM Tris.HCl pH 8.0, 2 mM EDTA, 100 mM NaCl, 1 mM phenylmethylsulphonyl uoride (PMSF), 0.5% Triton X100) and repelleting. The resulting pellet of insoluble protein was solubilized by mixing in 10 ml 5 M guanidine HCl, 50 mM Tris.HCl pH 8.0, 0.005% Tween 80, at 48C for 4 h. The remaining insoluble protein was pelleted as described above, and the supernatant diluted to a ®nal concentration of 1M guanidine HCl, 50 mM Tris.HCl pH 8.0, 2 mM reduced glutathione, 0.02 mM oxidized glutathione. Refolding of the protein was facilitated by gentle mixing at 48C for 12 ± 18 h followed by extensive dialysis against 50 mM Tris.HCl pH 8.0, 300 mM NaCl, 0.005% Tween 80. Remaining insoluble material was pelleted as described above.
Human E1 ubiquitin activating enzyme was puri®ed from recombinant baculovirus infected insect cells by anity chromatography on ubiquitin Sepharose as previously described (Desterro et al., 1999) . Human UbcH5 was expressed in bacteria and puri®ed as previously described (Desterro et al., 1997) . Ubiquitin was purchased from Sigma.
Peptide series, Pepscan ELISA and streptavidin bead pull down assays Peptide series were synthesized by Chiron Technologies with Nterminal biotin and a spacer arm, i.e. biotin-SGSG-peptide. Amino acid sequences are shown in Figure 1b . The sequence of the random peptide used in in vitro experiments was: biotin-SGSG-RMPLRFRPIRVARVGLRVCT. The freeze dried peptides were reconstituted in DMSO (1.6 mg in 200 ml or 3 mM) and diluted 1/1000 in 2% BSA, PBS for working stocks. For the Pepscan ELISA, 96-well plates were coated with streptavidin (100 ml of 5 mg/ml per well) and allowed to dry completely at 378C overnight. The plate was blocked with 2% BSA, PBS and washed four times in PBS, 0.2% Tween 20 (PBS-T). The working stock of diluted peptides was added (50 ml per well) and incubated for 1 h at 48C, then washed four times with PBS-T. The plate was blocked again with 5% milk, PBS-T for 2 h. Human Mdm2 protein puri®ed from bacteria was diluted to 0.5 mg/ml in 0.1% milk, PBS-T, and 50 ml per well was added and the plate incubated for 1 h at 48C, and washed four times with PBS-T. 50 ml per well of 4B2 ascites diluted 1 : 1000 in 5% milk, PBS-T was added and the plate was incubated at 48C for 1 h and washed four times with PBS-T. 50 ml of HRP conjugated anti-mouse secondary antibody (Dako) diluted 1 : 1000 in 5% milk, PBS-T was added to each well and the plate was incubated at 48C for 1 h then washed four times with PBS-T. Bound antibody was detected by the addition of 50 ml per well TMB solution (10 ml of 0.1 M Sodium acetate pH 6.0, 100 ml of 5 mg/ml 3'3'5'5'Tetramethylbenzidine, 10 ml of hydrogen peroxide solution). A blue colour develops after 20 min and 50 ml per well 1 M H 2 SO 4 was added so that absorbance could be measured in a plate reader at a wavelength of 450 nm.
For peptide pull down assays, streptavidin agarose beads (Sigma) were washed three times in PBS, then 0.2 ml of reconstituted peptide stock (1.6 mg in 200 ml DMSO) was added to 10 ml beads in 100 ml PBS and incubated at room temperature for 1 h. The beads were washed three times in PBS, added to the appropriate cell lysate or 35 S-methionine labelled in vitro translated protein prepared using the Promega TnT, T7 polymerase coupled transcription-translation rabbit reticulocyte lysate kit according to the manufacturers instructions, and incubated for 1 h on ice. The beads were washed three times with 0.5 M NaCl NP40 Lysis buer (0.5 M NaCl, 50 mM Tris.HCl pH 8.0, 5 mM EDTA, 1% NP40, 1 mM PMSF). 50 ml loading buer was added to the beads and co-precipitated proteins were analysed by 10% SDS polyacrylamide gel electrophoresis and autoradiography.
Immunopreciptations, gel electrophoresis and Western blotting
Cell lysates were prepared by lysing cells in electrophoresis sample buer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 10 mM EDTA, 0.007% bromophenol blue). DNA was sheared by passage through a 25G needle. The protein concentrations of the extracts were measured using the BCA protein assay (Pierce). After addition of DTT to a ®nal concentration of 100 mM total cell lysate (10 mg) or in vitro translation products (2 ml) were separated by 10% SDS-polyacrylamide gel electrophoresis, followed by drying and autoradiography, or transfer onto nitrocellulose membrane using a Biorad Mini Trans-blot Electrophoretic Transfer cell for 16 h, at 25 mA, at room temperature in 25 mM Tris HCl, 190 mM glycine, 20% methanol. Prestained molecular weight markers (Biorad) were run in parallel. Blots were blocked in 5% dried milk, 0.1% Tween 20 in PBS for 1 h at room temperature then incubated 1 h at room temperature with monoclonal antibodies (diluted 1 : 1000). Blots were washed in PBS, 0.1% Tween 20 then incubated for 1 h with peroxidase-conjugated anti-mouse Ig (Dako) diluted 1 : 2000, and bound antibodies were detected by enhanced chemiluminescence (Amersham).
Immunoprecipitations were performed as follows: 2 ml of in vitro translation lysates were incubated with 3 mg of protein A puri®ed antibody on ice for 1 h. The lysate was cleared of insoluble proteins by centrifugation at 14 000 g for 10 min at 48C. 50 ml of protein G beads washed in NP40 lysis buer (150 mM NaCl, 50 mM Tris.HCl pH 8.0, 5 mM EDTA, 1% NP40, 1 mM PMSF) was added and mixed for 1 h at 48C. The beads were washed several times in 0.5 M NaCl NP40 lysis buer. Beads were boiled in gel loading buer and SDS polyacrylamide gel electrophoresis was performed as described above.
Microinjection into cells
Cells grown on glass coverslips were injected with protein A puri®ed monoclonal antibodies (1 mg/ml) using the Eppendorf 5252 Microinjector and 5170 Micromanipulator. After a 24 h incubation cells were ®xed and stained for bgalactosidase expression.
Cell staining and b-galactosidase assays
To detect GFP proteins, cells grown on glass coverslips were washed with PBS then ®xed for 10 min in 4% paraformaldehyde at room temperature, permeabilized for 5 min in 0.2% Tween 20 and washed again in several changes of PBS. Cells were costained with CM1 rabbit serum diluted 1 : 1000 followed by Texas red conjugated anti-rabbit IgG (Dako) diluted 1 : 1000.
To detect p53-dependent transcriptional activation, T22 RGCDFosLacZ cells were microinjected with antibodies, or transfected with plasmids and after 24 ± 48 h were washed in PBS and ®xed with 2% formaldehyde in PBS for 5 min on ice. The cells were washed in PBS and overlaid with 0.25 mg/ ml X-Gal in reaction mix (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride in PBS) then incubated at 378C for 16 h.
For quantitative detection of b-galactosidase, 48 h after transfection, cells in 24-well plates were washed twice with PBS and lysed on the plate with 100 ml of reporter lysis buer (Promega) and incubated at room temperature for 2 h. Chlorophenol red b-D-galactopyranoside (CPRG, Boehringer) substrate solution (75 ml of 0.1 M MgCl 2 , 4.5 mM b mercaptoethanol and 250 ml of 4 mg/ml CPRG added to 12.5 ml of 0.1 M sodium phosphate buer, pH 7.5) was prepared and 300 ml added to each well. A red colour develops after several hours at room temperature and the assay was quantitated by absorbance measurements at a wavelength of 590 nm in a plate reader.
Thioester assay
Ubiquitin was radiolabelled with carrier-free Na-125 I (Amersham) by the Chloramine-T method (Ciechanover et al., 1980) . Formation of thioester adducts between recombinant E1 or UbcH5 and radiolabelled ubiquitin was determined essentially as previously described (Haas et al., 1982) . Reactions contained 100 ng of human E1, 1U of inorganic pyrophosphatase (Sigma), 0.5 mg of 125 I-ubiquitin and 100 ng of recombinant UbcH5 in a ®nal volume of 20 ml of 50 mM Tris.HCl pH 7.6, 10 mM MgCl 2 , 1 mM ATP. Peptide DMSO stocks (1.6 mg/200 ml or 3 mM) were diluted 1 : 50 in DMSO and 1 ml added to a 20 ml reaction. The reactions were incubated at 308C for 10 min and terminated by incubating the samples at 308C for 15 min in the presence of 2% (w/v) sodium dodecyl sulphate and 4 M Urea. Samples were subjected to SDS ± PAGE (12.5%) and dried gels analysed by phosphorimaging (Fujix BAS1500, MacBAS software).
In vitro p53 and Mdm2 ubiquitination assays 35 S-methionine labelled in vitro transcribed and translated p53 protein (1 ml) was incubated in a 10 ml reaction including an ATP regenerating system (50 mM Tris pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ml of creatine kinase and 0.6 U/ml of inorganic pyrophosphatase), 10 mg ubiquitin, 10 ng human E1, 60 ng UbcH5 and 60 ng of Mdm2. Peptide DMSO stocks (1.6 mg/200 ml or 3 mM) were diluted 1 : 50 in DMSO and 1 ml added to a 10 ml reaction. The reactions were incubated at 378C for 2 h. After terminating the reactions with SDS sample buer containing mercaptoethanol, reaction products were fractionated by SDS ± PAGE (10%) and the dried gels analysed by phosphorimaging (Fujix BAS 1500, MacBAS software).
In vitro ubiquitination using puri®ed proteins was accomplished in a 10 ml reaction containing 50 mM Tris pH 7.6, 5 mM MgCl 2 , 2 mM ATP, 10 mM creatine phosphate, 3.5 U/ ml of creatine kinase and 0.6 U/ml of inorganic pyrophosphatase, 0.6 mg of recombinant human p53, 0.5 mg 125 Iubiquitin, 40 ng of human E1, 80 ng UbcH5 and 80 ng of Mdm2. Peptides were added as above. Reactions were incubated at 378C for 2 h and the reactions products were treated as described above.
